{ "data": { "id": "org_roche", "slug": "roche", "name": "Roche", "short_name": "Roche", "type": "company", "tier": 2, "homepage": "https://www.roche.com", "country_code": "CH", "reliability_note": null, "url": "https://statorigin.org/sources/roche", "documents": [ { "title": "U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments", "url": "https://www.roche.com/media/releases/med-cor-2026-09-10", "doc_type": "press_release", "published_date": "2026-09-10", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 2 }, { "title": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "url": "https://www.roche.com/media/releases/med-cor-2026-08-20", "doc_type": "press_release", "published_date": "2026-08-20", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 8 }, { "title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "doc_type": "press_release", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 43 } ], "statistics": [ { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGD9", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD9", "indicator": { "slug": "countries-with-drug-approval", "name": "Countries with drug approval", "definition": "Number of countries in which a medicine has been granted regulatory approval for a given indication." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-10", "end": "2026-09-10", "type": "point" }, "value": 90, "value_text": "approximately 90 countries", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments", "document_url": "https://www.roche.com/media/releases/med-cor-2026-09-10", "document_type": "press_release", "locator": "About Enspryng (satralizumab)", "quote": "Enspryng is the first and only IL-6 inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the U.S. and E.U., with a well-established safety profile in over 10,000 patients.", "published_date": "2026-09-10", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-09-10. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD9", "bibtex": "@misc{roche2026countriesbjmgd9,\n author = {{Roche}},\n title = {U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD9},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDA", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA", "indicator": { "slug": "patients-treated-with-drug", "name": "Patients treated with drug", "definition": "Cumulative number of patients in whom a medicine has an established safety profile through clinical trials and post-approval use." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-10", "end": "2026-09-10", "type": "point" }, "value": 10000, "value_text": "over 10,000 patients", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments", "document_url": "https://www.roche.com/media/releases/med-cor-2026-09-10", "document_type": "press_release", "locator": "About Enspryng (satralizumab)", "quote": "Enspryng is the first and only IL-6 inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the U.S. and E.U., with a well-established safety profile in over 10,000 patients.", "published_date": "2026-09-10", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-09-10. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA", "bibtex": "@misc{roche2026patientsbjmgda,\n author = {{Roche}},\n title = {U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_XWVEPWH8A86STY8FSVZYJZ1WDN", "url": "https://statorigin.org/stat/stat_XWVEPWH8A86STY8FSVZYJZ1WDN", "indicator": { "slug": "company-countries-of-operation", "name": "Company countries of operation", "definition": "Total number of countries in which a healthcare company supplies and distributes pharmaceutical or diagnostic products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-08-20", "end": "2026-08-20", "type": "point" }, "value": 150, "value_text": "over 150", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "document_url": "https://www.roche.com/media/releases/med-cor-2026-08-20", "document_type": "press_release", "locator": "About Roche", "quote": "Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world.", "published_date": "2026-08-20", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). Roche’s US subsidiary Genentech announces manufacturing expansion in the United States. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-08-20. Via StatOrigin, https://statorigin.org/stat/stat_XWVEPWH8A86STY8FSVZYJZ1WDN", "bibtex": "@misc{roche2026companyjz1wdn,\n author = {{Roche}},\n title = {Roche’s US subsidiary Genentech announces manufacturing expansion in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_XWVEPWH8A86STY8FSVZYJZ1WDN},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-08-20. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_F34RHKHZS2FXGR5VF26CT43Z3Z", "url": "https://statorigin.org/stat/stat_F34RHKHZS2FXGR5VF26CT43Z3Z", "indicator": { "slug": "company-operating-locations", "name": "Company operating locations", "definition": "Total number of distinct operational locations maintained by a pharmaceutical company." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-08-20", "end": "2026-08-20", "type": "point" }, "value": 24, "value_text": "24", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "document_url": "https://www.roche.com/media/releases/med-cor-2026-08-20", "document_type": "press_release", "locator": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "quote": "Roche and Genentech’s current U.S. footprint includes 13 manufacturing sites, 15 research and development sites and approximately 25,000 employees across 24 locations in eight states.", "published_date": "2026-08-20", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). Roche’s US subsidiary Genentech announces manufacturing expansion in the United States. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-08-20. Via StatOrigin, https://statorigin.org/stat/stat_F34RHKHZS2FXGR5VF26CT43Z3Z", "bibtex": "@misc{roche2026companyt43z3z,\n author = {{Roche}},\n title = {Roche’s US subsidiary Genentech announces manufacturing expansion in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_F34RHKHZS2FXGR5VF26CT43Z3Z},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-08-20. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGET", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGET", "indicator": { "slug": "pharmaceutical-corporate-employment", "name": "Pharmaceutical corporate employment", "definition": "Total number of employees working for a pharmaceutical company within a specified region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-08-20", "end": "2026-08-20", "type": "point" }, "value": 25000, "value_text": "25,000", "unit": "count", "currency": null, "scale": "1", "value_type": "estimate", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "document_url": "https://www.roche.com/media/releases/med-cor-2026-08-20", "document_type": "press_release", "locator": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "quote": "Roche and Genentech’s current U.S. footprint includes 13 manufacturing sites, 15 research and development sites and approximately 25,000 employees across 24 locations in eight states.", "published_date": "2026-08-20", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). Roche’s US subsidiary Genentech announces manufacturing expansion in the United States. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-08-20. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGET", "bibtex": "@misc{roche2026pharmaceuticalbjmget,\n author = {{Roche}},\n title = {Roche’s US subsidiary Genentech announces manufacturing expansion in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGET},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-08-20. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEQ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEQ", "indicator": { "slug": "pharmaceutical-manufacturing-employment-creation", "name": "Pharmaceutical manufacturing employment creation", "definition": "Number of specialized pharmaceutical manufacturing jobs expected to be created through a new facility or expansion." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-08-20", "end": "2026-08-20", "type": "point" }, "value": 250, "value_text": "250", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "document_url": "https://www.roche.com/media/releases/med-cor-2026-08-20", "document_type": "press_release", "locator": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "quote": "Approximately $750 million investment will double the size of the existing facility and is expected to create an additional 250 specialised manufacturing jobs.", "published_date": "2026-08-20", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). Roche’s US subsidiary Genentech announces manufacturing expansion in the United States. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-08-20. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEQ", "bibtex": "@misc{roche2026pharmaceuticalbjmgeq,\n author = {{Roche}},\n title = {Roche’s US subsidiary Genentech announces manufacturing expansion in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEQ},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-08-20. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGER", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGER", "indicator": { "slug": "pharmaceutical-manufacturing-employment-creation", "name": "Pharmaceutical manufacturing employment creation", "definition": "Number of specialized pharmaceutical manufacturing jobs expected to be created through a new facility or expansion." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-08-20", "end": "2031-12-31", "type": "point" }, "value": 250, "value_text": "250", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "document_url": "https://www.roche.com/media/releases/med-cor-2026-08-20", "document_type": "press_release", "locator": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "quote": "The investment is expected to create 250 high-wage manufacturing jobs and approximately 200 construction jobs in Oregon during site development, with commercial operations expected to begin in 2031.", "published_date": "2026-08-20", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). Roche’s US subsidiary Genentech announces manufacturing expansion in the United States. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-08-20. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGER", "bibtex": "@misc{roche2026pharmaceuticalbjmger,\n author = {{Roche}},\n title = {Roche’s US subsidiary Genentech announces manufacturing expansion in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGER},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-08-20. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEP", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEP", "indicator": { "slug": "pharmaceutical-manufacturing-facility-capital-investment", "name": "Pharmaceutical manufacturing facility capital investment", "definition": "Total planned capital expenditure and investment in pharmaceutical manufacturing and fill-finish facilities." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-08-20", "end": "2026-08-20", "type": "point" }, "value": 750, "value_text": "$750 million", "unit": "USD", "currency": "USD", "scale": "million", "value_type": "forecast", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "document_url": "https://www.roche.com/media/releases/med-cor-2026-08-20", "document_type": "press_release", "locator": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "quote": "Approximately $750 million investment will double the size of the existing facility and is expected to create an additional 250 specialised manufacturing jobs.", "published_date": "2026-08-20", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). Roche’s US subsidiary Genentech announces manufacturing expansion in the United States. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-08-20. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEP", "bibtex": "@misc{roche2026pharmaceuticalbjmgep,\n author = {{Roche}},\n title = {Roche’s US subsidiary Genentech announces manufacturing expansion in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEP},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-08-20. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGES", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGES", "indicator": { "slug": "pharmaceutical-manufacturing-sites", "name": "Pharmaceutical manufacturing sites", "definition": "Total number of operational pharmaceutical manufacturing facilities in a specified region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-08-20", "end": "2026-08-20", "type": "point" }, "value": 13, "value_text": "13", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "document_url": "https://www.roche.com/media/releases/med-cor-2026-08-20", "document_type": "press_release", "locator": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "quote": "Roche and Genentech’s current U.S. footprint includes 13 manufacturing sites, 15 research and development sites and approximately 25,000 employees across 24 locations in eight states.", "published_date": "2026-08-20", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). Roche’s US subsidiary Genentech announces manufacturing expansion in the United States. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-08-20. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGES", "bibtex": "@misc{roche2026pharmaceuticalbjmges,\n author = {{Roche}},\n title = {Roche’s US subsidiary Genentech announces manufacturing expansion in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGES},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-08-20. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_4VST58MPECCZVS4P4Q8NN6FMWN", "url": "https://statorigin.org/stat/stat_4VST58MPECCZVS4P4Q8NN6FMWN", "indicator": { "slug": "pharmaceutical-research-and-development-sites", "name": "Pharmaceutical research and development sites", "definition": "Total number of facilities dedicated to pharmaceutical research and development activities." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-08-20", "end": "2026-08-20", "type": "point" }, "value": 15, "value_text": "15", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "document_url": "https://www.roche.com/media/releases/med-cor-2026-08-20", "document_type": "press_release", "locator": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "quote": "Roche and Genentech’s current U.S. footprint includes 13 manufacturing sites, 15 research and development sites and approximately 25,000 employees across 24 locations in eight states.", "published_date": "2026-08-20", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). Roche’s US subsidiary Genentech announces manufacturing expansion in the United States. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-08-20. Via StatOrigin, https://statorigin.org/stat/stat_4VST58MPECCZVS4P4Q8NN6FMWN", "bibtex": "@misc{roche2026pharmaceuticaln6fmwn,\n author = {{Roche}},\n title = {Roche’s US subsidiary Genentech announces manufacturing expansion in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_4VST58MPECCZVS4P4Q8NN6FMWN},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-08-20. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDX", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDX", "indicator": { "slug": "core-diluted-earnings-per-share", "name": "Core diluted earnings per share", "definition": "Core earnings per share calculated on a diluted basis." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 10.85, "value_text": "10.85", "unit": "CHF", "currency": "CHF", "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Key figures CHF millions % change", "quote": "Core EPS – diluted (CHF) 10.85 11.08 9 -2", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDX", "bibtex": "@misc{roche2026corebjmgdx,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDX},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDY", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDY", "indicator": { "slug": "core-diluted-earnings-per-share", "name": "Core diluted earnings per share", "definition": "Core earnings per share calculated on a diluted basis." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-06-30", "type": "quarter" }, "value": 11.08, "value_text": "11.08", "unit": "CHF", "currency": "CHF", "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Key figures CHF millions % change", "quote": "Core EPS – diluted (CHF) 10.85 11.08 9 -2", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDY", "bibtex": "@misc{roche2026corebjmgdy,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDY},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDZ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDZ", "indicator": { "slug": "core-diluted-earnings-per-share-growth-at-constant-exchange-rates", "name": "Core diluted earnings per share growth at constant exchange rates", "definition": "Percentage change in diluted core earnings per share calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 9, "value_text": "9", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Key figures CHF millions % change", "quote": "Core EPS – diluted (CHF) 10.85 11.08 9 -2", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDZ", "bibtex": "@misc{roche2026corebjmgdz,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDZ},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGE0", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE0", "indicator": { "slug": "core-diluted-earnings-per-share-growth-in-swiss-francs", "name": "Core diluted earnings per share growth in Swiss francs", "definition": "Percentage change in diluted core earnings per share reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -2, "value_text": "-2", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Key figures CHF millions % change", "quote": "Core EPS – diluted (CHF) 10.85 11.08 9 -2", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE0", "bibtex": "@misc{roche2026corebjmge0,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE0},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDM", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDM", "indicator": { "slug": "core-earnings-per-share-growth-at-constant-exchange-rates", "name": "Core earnings per share growth at constant exchange rates", "definition": "Percentage change in core earnings per share calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 9, "value_text": "+9%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Core earnings per share were +9% at CER (-2% in CHF); IFRS diluted earnings per share were -8% in CHF due to the appreciation of the Swiss franc.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDM", "bibtex": "@misc{roche2026corebjmgdm,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDM},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDN", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDN", "indicator": { "slug": "core-earnings-per-share-growth-in-swiss-francs", "name": "Core earnings per share growth in Swiss francs", "definition": "Percentage change in core earnings per share reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -2, "value_text": "-2%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Core earnings per share were +9% at CER (-2% in CHF); IFRS diluted earnings per share were -8% in CHF due to the appreciation of the Swiss franc.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDN", "bibtex": "@misc{roche2026corebjmgdn,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDN},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDV", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDV", "indicator": { "slug": "core-operating-profit", "name": "Core operating profit", "definition": "Operating profit before exceptional items and certain non-core business activities." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 11.9, "value_text": "CHF 11.9 billion", "unit": "CHF", "currency": "CHF", "scale": "billion", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "Core operating profit was +10% at CER (-1% in CHF) to CHF 11.9 billion, driven by higher sales and other revenue.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDV", "bibtex": "@misc{roche2026corebjmgdv,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDV},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDW", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDW", "indicator": { "slug": "core-operating-profit", "name": "Core operating profit", "definition": "Operating profit before exceptional items and certain non-core business activities." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-06-30", "type": "quarter" }, "value": 12010, "value_text": "12,010", "unit": "CHF", "currency": "CHF", "scale": "million", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Key figures CHF millions % change", "quote": "Core operating profit 11,856 12,010 10 -1", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDW", "bibtex": "@misc{roche2026corebjmgdw,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDW},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_KYVA9B5GJX5DD2MTEGK0DQWH47", "url": "https://statorigin.org/stat/stat_KYVA9B5GJX5DD2MTEGK0DQWH47", "indicator": { "slug": "core-operating-profit-half-year", "name": "Core operating profit (half year)", "definition": "Operating profit adjusted for significant non-core items to reflect underlying business performance." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 11856, "value_text": "11,856", "unit": "CHF", "currency": "CHF", "scale": "million", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Key figures CHF millions % change", "quote": "Core operating profit 11,856 12,010 10 -1", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_KYVA9B5GJX5DD2MTEGK0DQWH47", "bibtex": "@misc{roche2026coredqwh47,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KYVA9B5GJX5DD2MTEGK0DQWH47},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDH", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDH", "indicator": { "slug": "core-operating-profit-growth-at-constant-exchange-rates", "name": "Core operating profit growth at constant exchange rates", "definition": "Percentage change in core operating profit calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 10, "value_text": "+10%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Core operating profit was +10% at CER, -1% when reported in CHF, driven by higher sales and other revenue; IFRS operating profit was -6% in CHF due to the appreciation of the Swiss franc.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDH", "bibtex": "@misc{roche2026corebjmgdh,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDH},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDJ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDJ", "indicator": { "slug": "core-operating-profit-growth-in-swiss-francs", "name": "Core operating profit growth in Swiss francs", "definition": "Percentage change in core operating profit reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -1, "value_text": "-1%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Core operating profit was +10% at CER, -1% when reported in CHF, driven by higher sales and other revenue; IFRS operating profit was -6% in CHF due to the appreciation of the Swiss franc.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDJ", "bibtex": "@misc{roche2026corebjmgdj,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDJ},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDQ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDQ", "indicator": { "slug": "group-sales", "name": "Group sales", "definition": "Total revenue generated from the sale of goods and services by the group over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 30.4, "value_text": "CHF 30.4 billion", "unit": "CHF", "currency": "CHF", "scale": "billion", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In the first six months of 2026, Roche sales were +6% at CER, -2% when reported in CHF, to CHF 30.4 billion due to strong demand for pharmaceutical products and diagnostic solutions.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDQ", "bibtex": "@misc{roche2026groupbjmgdq,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDQ},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDB", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDB", "indicator": { "slug": "group-sales-growth-at-constant-exchange-rates", "name": "Group sales growth at constant exchange rates", "definition": "Percentage change in total group sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 6, "value_text": "+6%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDB", "bibtex": "@misc{roche2026groupbjmgdb,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDB},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDC", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDC", "indicator": { "slug": "group-sales-growth-in-swiss-francs", "name": "Group sales growth in Swiss francs", "definition": "Percentage change in total group sales reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -2, "value_text": "-2%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDC", "bibtex": "@misc{roche2026groupbjmgdc,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDC},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDD", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDD", "indicator": { "slug": "group-sales-growth-in-us-dollars", "name": "Group sales growth in US dollars", "definition": "Percentage change in total group sales reported in US dollars over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 8, "value_text": "+8%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDD", "bibtex": "@misc{roche2026groupbjmgdd,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDD},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDP", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDP", "indicator": { "slug": "ifrs-diluted-earnings-per-share-growth-in-swiss-francs", "name": "IFRS diluted earnings per share growth in Swiss francs", "definition": "Percentage change in IFRS diluted earnings per share reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -8, "value_text": "-8%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Core earnings per share were +9% at CER (-2% in CHF); IFRS diluted earnings per share were -8% in CHF due to the appreciation of the Swiss franc.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDP", "bibtex": "@misc{roche2026ifrsbjmgdp,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDP},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGE1", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE1", "indicator": { "slug": "ifrs-operating-profit", "name": "IFRS operating profit", "definition": "Operating profit determined under International Financial Reporting Standards." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 9.7, "value_text": "CHF 9.7 billion", "unit": "CHF", "currency": "CHF", "scale": "billion", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "IFRS operating profit was -6% in CHF to CHF 9.7 billion.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE1", "bibtex": "@misc{roche2026ifrsbjmge1,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE1},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGE2", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE2", "indicator": { "slug": "ifrs-operating-profit", "name": "IFRS operating profit", "definition": "Operating profit determined under International Financial Reporting Standards." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-06-30", "type": "quarter" }, "value": 10330, "value_text": "10,330", "unit": "CHF", "currency": "CHF", "scale": "million", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Key figures CHF millions % change", "quote": "IFRS operating profit 9,671 10,330 6 -6", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE2", "bibtex": "@misc{roche2026ifrsbjmge2,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE2},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_MZ6KX41B6PX994KZ2DR19WWPN9", "url": "https://statorigin.org/stat/stat_MZ6KX41B6PX994KZ2DR19WWPN9", "indicator": { "slug": "ifrs-operating-profit-half-year", "name": "IFRS operating profit (half year)", "definition": "Operating profit determined according to International Financial Reporting Standards." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 9671, "value_text": "9,671", "unit": "CHF", "currency": "CHF", "scale": "million", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Key figures CHF millions % change", "quote": "IFRS operating profit 9,671 10,330 6 -6", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_MZ6KX41B6PX994KZ2DR19WWPN9", "bibtex": "@misc{roche2026ifrs9wwpn9,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_MZ6KX41B6PX994KZ2DR19WWPN9},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGE3", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE3", "indicator": { "slug": "ifrs-operating-profit-growth-at-constant-exchange-rates", "name": "IFRS operating profit growth at constant exchange rates", "definition": "Percentage change in IFRS operating profit calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 6, "value_text": "6", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Key figures CHF millions % change", "quote": "IFRS operating profit 9,671 10,330 6 -6", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE3", "bibtex": "@misc{roche2026ifrsbjmge3,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE3},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDK", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDK", "indicator": { "slug": "ifrs-operating-profit-growth-in-swiss-francs", "name": "IFRS operating profit growth in Swiss francs", "definition": "Percentage change in IFRS operating profit reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -6, "value_text": "-6%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Core operating profit was +10% at CER, -1% when reported in CHF, driven by higher sales and other revenue; IFRS operating profit was -6% in CHF due to the appreciation of the Swiss franc.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDK", "bibtex": "@misc{roche2026ifrsbjmgdk,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDK},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGE6", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE6", "indicator": { "slug": "off-patent-products-sales", "name": "Off-patent products sales", "definition": "Total sales of medicines with expired patents over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 2.6, "value_text": "CHF 2.6 billion", "unit": "CHF", "currency": "CHF", "scale": "billion", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "Sales of products with expired patents (Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra) were CHF 2.6 billion, a decrease of 8% at CER, or 15% in CHF, compared to the first six months of 2025.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE6", "bibtex": "@misc{roche2026patentbjmge6,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE6},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDS", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDS", "indicator": { "slug": "pharmaceuticals-division-sales", "name": "Pharmaceuticals division sales", "definition": "Revenue generated by the pharmaceuticals division over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 23.6, "value_text": "CHF 23.6 billion", "unit": "CHF", "currency": "CHF", "scale": "billion", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "Sales in the Pharmaceuticals Division were +6% at CER, -1% when reported in CHF, to CHF 23.6 billion, with our medicines across disease areas continuing their strong growth.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDS", "bibtex": "@misc{roche2026pharmaceuticalsbjmgds,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDS},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDE", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDE", "indicator": { "slug": "pharmaceuticals-division-sales-growth-at-constant-exchange-rates", "name": "Pharmaceuticals division sales growth at constant exchange rates", "definition": "Percentage change in pharmaceuticals division sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 6, "value_text": "+6%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Pharmaceuticals Division sales were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales of our medicines across disease areas; Xolair (allergic asthma, chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDE", "bibtex": "@misc{roche2026pharmaceuticalsbjmgde,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDE},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDF", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDF", "indicator": { "slug": "pharmaceuticals-division-sales-growth-in-swiss-francs", "name": "Pharmaceuticals division sales growth in Swiss francs", "definition": "Percentage change in pharmaceuticals division sales reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -1, "value_text": "-1%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Pharmaceuticals Division sales were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales of our medicines across disease areas; Xolair (allergic asthma, chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDF", "bibtex": "@misc{roche2026pharmaceuticalsbjmgdf,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDF},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDG", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDG", "indicator": { "slug": "pharmaceuticals-division-sales-growth-in-us-dollars", "name": "Pharmaceuticals division sales growth in US dollars", "definition": "Percentage change in pharmaceuticals division sales reported in US dollars over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 8, "value_text": "+8%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc", "quote": "Pharmaceuticals Division sales were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales of our medicines across disease areas; Xolair (allergic asthma, chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDG", "bibtex": "@misc{roche2026pharmaceuticalsbjmgdg,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDG},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGE4", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE4", "indicator": { "slug": "sales-growth-at-constant-exchange-rates", "name": "Sales growth at constant exchange rates", "definition": "Percentage change in sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 3, "value_text": "+3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "Sales in the Europe, Middle East and Africa (EMEA) region were +3% at CER, -1% when reported in CHF, driven by higher sales of immunodiagnostic products, the clinical chemistry portfolio and molecular solutions.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE4", "bibtex": "@misc{roche2026salesbjmge4,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE4},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGE7", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE7", "indicator": { "slug": "sales-growth-at-constant-exchange-rates", "name": "Sales growth at constant exchange rates", "definition": "Percentage change in sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 6, "value_text": "+6%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In the United States, sales were +6% at CER, -3% when reported in CHF, due to continued growth of Xolair, Hemlibra, Polivy (blood cancer) and Tecentriq.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE7", "bibtex": "@misc{roche2026salesbjmge7,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE7},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGE9", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE9", "indicator": { "slug": "sales-growth-at-constant-exchange-rates", "name": "Sales growth at constant exchange rates", "definition": "Percentage change in sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 1, "value_text": "+1%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "Sales in Europe were +1% at CER, or -1% when reported in CHF, as demand for Ocrevus, Evrysdi (spinal muscular atrophy) and Phesgo more than offset the impact of lower sales of Actemra/RoActemra due to biosimilar competition and Perjeta because of the conversion of patients to Phesgo.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE9", "bibtex": "@misc{roche2026salesbjmge9,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE9},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEB", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEB", "indicator": { "slug": "sales-growth-at-constant-exchange-rates", "name": "Sales growth at constant exchange rates", "definition": "Percentage change in sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "JP", "name": "Japan", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 11, "value_text": "+11%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In Japan, sales were +11% at CER, -5% when reported in CHF, mainly due to product supply to third parties, as well as the uptake of Elevidys (Duchenne muscular dystrophy) and continued growth of Lunsumio (blood cancer), Vabysmo and Hemlibra.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEB", "bibtex": "@misc{roche2026salesbjmgeb,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEB},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEE", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEE", "indicator": { "slug": "sales-growth-at-constant-exchange-rates", "name": "Sales growth at constant exchange rates", "definition": "Percentage change in sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -9, "value_text": "-9%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In China, sales were -9% at CER, or -12% when reported in CHF, due to the base effect of a severe flu season in 2025 on Xofluza sales.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEE", "bibtex": "@misc{roche2026salesbjmgee,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEE},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEG", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEG", "indicator": { "slug": "sales-growth-at-constant-exchange-rates", "name": "Sales growth at constant exchange rates", "definition": "Percentage change in sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "NAMERICA", "name": "North America", "type": "bloc" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 8, "value_text": "+8%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In North America, sales were +8% at CER, -1% when reported in CHF, due to growth across the Core Lab and Pathology Lab customer areas.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEG", "bibtex": "@misc{roche2026salesbjmgeg,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEG},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEJ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEJ", "indicator": { "slug": "sales-growth-at-constant-exchange-rates", "name": "Sales growth at constant exchange rates", "definition": "Percentage change in sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "APAC", "name": "Asia-Pacific", "type": "bloc" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -5, "value_text": "-5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "Sales in Asia-Pacific were -5% at CER, or -12% when reported in CHF, mainly due to the healthcare pricing reforms in China, partially offset by growth in demand for clinical chemistry and immunodiagnostic products across the rest of the region.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEJ", "bibtex": "@misc{roche2026salesbjmgej,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEJ},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEM", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEM", "indicator": { "slug": "sales-growth-at-constant-exchange-rates", "name": "Sales growth at constant exchange rates", "definition": "Percentage change in sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "LATAM", "name": "Latin America and the Caribbean", "type": "bloc" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 10, "value_text": "+10%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In Latin America, sales were +10% at CER, or +5% when reported in CHF.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEM", "bibtex": "@misc{roche2026salesbjmgem,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEM},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGE8", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE8", "indicator": { "slug": "sales-growth-in-swiss-francs", "name": "Sales growth in Swiss francs", "definition": "Percentage change in sales reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -3, "value_text": "-3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In the United States, sales were +6% at CER, -3% when reported in CHF, due to continued growth of Xolair, Hemlibra, Polivy (blood cancer) and Tecentriq.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE8", "bibtex": "@misc{roche2026salesbjmge8,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE8},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEA", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEA", "indicator": { "slug": "sales-growth-in-swiss-francs", "name": "Sales growth in Swiss francs", "definition": "Percentage change in sales reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "EU", "name": "European Union", "type": "bloc" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -1, "value_text": "-1%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "Sales in Europe were +1% at CER, or -1% when reported in CHF, as demand for Ocrevus, Evrysdi (spinal muscular atrophy) and Phesgo more than offset the impact of lower sales of Actemra/RoActemra due to biosimilar competition and Perjeta because of the conversion of patients to Phesgo.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEA", "bibtex": "@misc{roche2026salesbjmgea,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEA},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEC", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEC", "indicator": { "slug": "sales-growth-in-swiss-francs", "name": "Sales growth in Swiss francs", "definition": "Percentage change in sales reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "JP", "name": "Japan", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -5, "value_text": "-5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In Japan, sales were +11% at CER, -5% when reported in CHF, mainly due to product supply to third parties, as well as the uptake of Elevidys (Duchenne muscular dystrophy) and continued growth of Lunsumio (blood cancer), Vabysmo and Hemlibra.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEC", "bibtex": "@misc{roche2026salesbjmgec,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEC},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGED", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGED", "indicator": { "slug": "sales-growth-in-swiss-francs", "name": "Sales growth in Swiss francs", "definition": "Percentage change in sales reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -1, "value_text": "-1%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "Sales in the Europe, Middle East and Africa (EMEA) region were +3% at CER, -1% when reported in CHF, driven by higher sales of immunodiagnostic products, the clinical chemistry portfolio and molecular solutions.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGED", "bibtex": "@misc{roche2026salesbjmged,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGED},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEF", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEF", "indicator": { "slug": "sales-growth-in-swiss-francs", "name": "Sales growth in Swiss francs", "definition": "Percentage change in sales reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -12, "value_text": "-12%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In China, sales were -9% at CER, or -12% when reported in CHF, due to the base effect of a severe flu season in 2025 on Xofluza sales.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEF", "bibtex": "@misc{roche2026salesbjmgef,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEF},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEH", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEH", "indicator": { "slug": "sales-growth-in-swiss-francs", "name": "Sales growth in Swiss francs", "definition": "Percentage change in sales reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "NAMERICA", "name": "North America", "type": "bloc" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -1, "value_text": "-1%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In North America, sales were +8% at CER, -1% when reported in CHF, due to growth across the Core Lab and Pathology Lab customer areas.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEH", "bibtex": "@misc{roche2026salesbjmgeh,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEH},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEK", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEK", "indicator": { "slug": "sales-growth-in-swiss-francs", "name": "Sales growth in Swiss francs", "definition": "Percentage change in sales reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "APAC", "name": "Asia-Pacific", "type": "bloc" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -12, "value_text": "-12%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "Sales in Asia-Pacific were -5% at CER, or -12% when reported in CHF, mainly due to the healthcare pricing reforms in China, partially offset by growth in demand for clinical chemistry and immunodiagnostic products across the rest of the region.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEK", "bibtex": "@misc{roche2026salesbjmgek,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEK},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEN", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEN", "indicator": { "slug": "sales-growth-in-swiss-francs", "name": "Sales growth in Swiss francs", "definition": "Percentage change in sales reported in Swiss francs over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "LATAM", "name": "Latin America and the Caribbean", "type": "bloc" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 5, "value_text": "+5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "In Latin America, sales were +10% at CER, or +5% when reported in CHF.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEN", "bibtex": "@misc{roche2026salesbjmgen,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEN},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGE5", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE5", "indicator": { "slug": "top-growth-drivers-sales", "name": "Top growth drivers sales", "definition": "Total sales generated by the top growth driver medicines over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 11, "value_text": "CHF 11.0 billion", "unit": "CHF", "currency": "CHF", "scale": "billion", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...", "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23", "document_type": "press_release", "locator": "Group results", "quote": "The top five growth drivers – Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo – achieved total sales of CHF 11.0 billion, an increase of 12% at CER, or 4% in CHF, compared to the first six months of 2025.", "published_date": "2026-07-23", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE5", "bibtex": "@misc{roche2026growthbjmge5,\n author = {{Roche}},\n title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE5},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" } ] }, "meta": { "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.", "license": "https://creativecommons.org/licenses/by/4.0/", "docs": "https://statorigin.org/docs/api", "total": 53, "note": "Statistics are capped at 100 per request. Use /statistics?source_org=roche with a cursor to page through everything." } }